1
|
Inoue M, Okamoto Y, Atsumi Y, Shiojiri M, Hidaka M, Tanaka T, Tsutsumi T, Shirasaka N, Tokumura A. Addition of high load of lysophosphatidic acid to standard and high-fat chows causes no significant changes of its circulating and peripheral tissue levels but affects body weight and visceral fat mass of mice. Biofactors 2018; 44:548-557. [PMID: 30368958 DOI: 10.1002/biof.1451] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 08/08/2018] [Accepted: 08/09/2018] [Indexed: 01/17/2023]
Abstract
Oral administration of lysophosphatidic acid (LPA), a critical intercellular lipid mediator, exerts wound healing and antiulcer effects on gastrointestinal system. To evaluate effects of food-derived LPA on body homeostasis, we measured LPA levels by liquid chromatography-tandem mass spectrometry in chows, feces, plasma, liver, and visceral fat of mice fed a normal or high-fat chow supplemented with or without LPA-rich soybean phospholipids for 30 days. Reductions in daily body weight gains and visceral fat mass were mainly related to lower chow intake by mice fed the LPA-rich high-fat chow, whereas reduced body weight gains and fat mass were mainly related to decreased intestinal triacylglycerol absorption in mice fed LPA-rich chow. Our results showed no significant increase in plasma, liver, or adipose LPA levels, even if a quite high LPA concentration (2.0%) in chows was ingested daily, suggesting limited effects of food-derived LPA on the lumen side of the digestive tract. © 2018 BioFactors, 44(6):548-557, 2018.
Collapse
Affiliation(s)
- Manami Inoue
- Department of Pharmaceutical Health Chemistry, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Yoko Okamoto
- Department of Pharmaceutical Health Chemistry, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Yuta Atsumi
- Bio Chemicals Department, Enzymes Division, Product Development Section, Nagase ChemteX Corporation, Fukuchiyama, Kyoto, Japan
| | - Masatoshi Shiojiri
- Bio Chemicals Department, Enzymes Division, Product Development Section, Nagase ChemteX Corporation, Fukuchiyama, Kyoto, Japan
| | - Mayumi Hidaka
- Department of Life Sciences, Faculty of Pharmacy, Yasuda Women's University, Asaminamiku, Hiroshima, Japan
| | - Tamotsu Tanaka
- Department of Pharmaceutical Health Chemistry, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan
| | - Toshihiko Tsutsumi
- Department of Pharmaceutics, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare, Nobeoka, Japan
| | - Naoki Shirasaka
- Bio Chemicals Department, Enzymes Division, Product Development Section, Nagase ChemteX Corporation, Fukuchiyama, Kyoto, Japan
| | - Akira Tokumura
- Department of Pharmaceutical Health Chemistry, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan
- Department of Life Sciences, Faculty of Pharmacy, Yasuda Women's University, Asaminamiku, Hiroshima, Japan
| |
Collapse
|